HSP90AA1 and urinary bladder cancer: Furthermore, pharmacogenomic screening identified several potential small-molecule inhibitors—alvespimycin, tanespimycin, and retaspimycin—that selectively target HSP90AA1 and may hold promise in sensitizing bladder cancer to immunotherapy.